DK3039038T3 - Fusionskonstruktion med antiserumalbumin-fab-effektordel, og fremstillingsmetode dertil - Google Patents
Fusionskonstruktion med antiserumalbumin-fab-effektordel, og fremstillingsmetode dertil Download PDFInfo
- Publication number
- DK3039038T3 DK3039038T3 DK14839630.2T DK14839630T DK3039038T3 DK 3039038 T3 DK3039038 T3 DK 3039038T3 DK 14839630 T DK14839630 T DK 14839630T DK 3039038 T3 DK3039038 T3 DK 3039038T3
- Authority
- DK
- Denmark
- Prior art keywords
- effector part
- manufacture therefor
- fusion construction
- antiserum albumin
- fab effector
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/53—Colony-stimulating factor [CSF]
- C07K14/535—Granulocyte CSF; Granulocyte-macrophage CSF
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/555—Interferons [IFN]
- C07K14/565—IFN-beta
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/61—Growth hormone [GH], i.e. somatotropin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/46—Hybrid immunoglobulins
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/67—General methods for enhancing the expression
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/76—Albumins
- C07K14/765—Serum albumin, e.g. HSA
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
- C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/35—Fusion polypeptide containing a fusion for enhanced stability/folding during expression, e.g. fusions with chaperones or thioredoxin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
- C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor
- C07K2319/75—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor containing a fusion for activation of a cell surface receptor, e.g. thrombopoeitin, NPY and other peptide hormones
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Genetics & Genomics (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Medicinal Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Zoology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Wood Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- Toxicology (AREA)
- Gastroenterology & Hepatology (AREA)
- Endocrinology (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR20130104112 | 2013-08-30 | ||
| PCT/KR2014/008106 WO2015030539A1 (en) | 2013-08-30 | 2014-08-29 | An anti serum albumin fab-effector moiety fusion construct, and the preparing method thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK3039038T3 true DK3039038T3 (da) | 2021-02-08 |
Family
ID=52586989
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK14839630.2T DK3039038T3 (da) | 2013-08-30 | 2014-08-29 | Fusionskonstruktion med antiserumalbumin-fab-effektordel, og fremstillingsmetode dertil |
Country Status (16)
| Country | Link |
|---|---|
| US (2) | US9879077B2 (https=) |
| EP (2) | EP3632930A1 (https=) |
| JP (2) | JP6422977B2 (https=) |
| KR (2) | KR101576561B1 (https=) |
| CN (1) | CN105899532B (https=) |
| AU (1) | AU2014312456B2 (https=) |
| BR (1) | BR112016004355A2 (https=) |
| CA (1) | CA2922618C (https=) |
| DK (1) | DK3039038T3 (https=) |
| ES (1) | ES2866848T3 (https=) |
| MX (1) | MX371328B (https=) |
| PH (1) | PH12016500403A1 (https=) |
| PL (1) | PL3039038T3 (https=) |
| RU (1) | RU2661087C2 (https=) |
| UA (1) | UA117493C2 (https=) |
| WO (1) | WO2015030539A1 (https=) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN108623691B (zh) * | 2017-03-17 | 2020-05-15 | 北京比洋生物技术有限公司 | IgG样长效免疫融合蛋白及其应用 |
| EP3806889A4 (en) * | 2018-06-18 | 2022-07-13 | Anwita Biosciences, Inc. | CYTOKI FUSION PROTEINS AND USES THEREOF |
| CN113710229B (zh) | 2019-02-25 | 2026-01-06 | 芝加哥大学 | 用与抗炎剂连接的ecm亲和肽治疗炎症性和自身免疫性病症的方法和组合物 |
| KR20210095781A (ko) | 2020-01-24 | 2021-08-03 | 주식회사 에이프릴바이오 | 항원결합 단편 및 생리활성 이펙터 모이어티로 구성된 융합 컨스트럭트를 포함하는 다중결합항체 및 이를 포함하는 약학조성물 |
| KR102485892B1 (ko) * | 2020-04-09 | 2023-01-09 | 주식회사 에이프릴바이오 | 고양이 과립구 집락 자극인자 및 혈청 알부민에 대한 항원 결합 단편을 포함하는 융합 단백질 및 이의 용도 |
| KR20220044057A (ko) * | 2020-09-29 | 2022-04-06 | 주식회사 에이프릴바이오 | 인터루킨-18 결합 단백질 및 혈청 알부민에 대한 항원 결합 단편을 포함하는 융합 단백질, 및 이의 용도 |
| IL317593A (en) * | 2022-06-15 | 2025-02-01 | UCB Biopharma SRL | Follistatin-FC fusion proteins |
| KR20240048577A (ko) * | 2022-10-04 | 2024-04-16 | 주식회사 에이프릴바이오 | 난포자극 호르몬 및 혈청 알부민에 대한 항원 결합 단편을 포함하는 융합 단백질 및 이의 용도 |
| WO2025253161A1 (en) * | 2024-06-05 | 2025-12-11 | Aprilbio Co., Ltd. | Methods for treating liver diseases using recombinant fusion proteins comprising interleukin-18-binding protein and antigen binding fragment to serum albumin |
| CN118393137B (zh) * | 2024-07-01 | 2024-08-20 | 广东赛尔生物科技有限公司 | 一种肠道保护菌的检测试剂盒及其应用 |
Family Cites Families (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW517061B (en) * | 1996-03-29 | 2003-01-11 | Pharmacia & Amp Upjohn Ab | Modified/chimeric superantigens and their use |
| ES2263984T3 (es) * | 2002-06-28 | 2006-12-16 | Domantis Limited | Ligandos doble-especificos con una vida media serica aumentada. |
| US9321832B2 (en) * | 2002-06-28 | 2016-04-26 | Domantis Limited | Ligand |
| GB0315450D0 (en) * | 2003-07-01 | 2003-08-06 | Celltech R&D Ltd | Biological products |
| EA012622B1 (ru) * | 2004-06-01 | 2009-10-30 | Домэнтис Лимитед | Биспецифичные гибридные антитела с увеличенным периодом полувыведения из сыворотки |
| CN101031588A (zh) * | 2004-06-01 | 2007-09-05 | 多曼蒂斯有限公司 | 药物组合物，融合物和结合物 |
| BRPI0514259A (pt) * | 2004-08-11 | 2008-06-03 | Trubion Pharmaceuticals Inc | proteìna de fusão de domìnio de ligação |
| JP2008515889A (ja) * | 2004-10-05 | 2008-05-15 | ジェネンテック・インコーポレーテッド | 毒性の低下した治療剤 |
| EP2024396A2 (en) * | 2004-12-02 | 2009-02-18 | Domantis Limited | Plad domain peptides with increased serum half life due to conjugation to domain antibodies |
| CA2596925C (en) * | 2005-02-08 | 2017-07-04 | Km Biologics Co., Ltd. | Method for improving expression level and stability of antibody |
| AU2008261042A1 (en) * | 2007-06-08 | 2008-12-11 | Dow Global Technologies Inc. | Expression of soluble antibody fragment by truncation of CH1 domain |
| WO2009040562A1 (en) * | 2007-09-26 | 2009-04-02 | Ucb Pharma S.A. | Dual specificity antibody fusions |
| CA2721093A1 (en) * | 2008-04-11 | 2009-10-15 | Merrimack Pharmaceuticals, Inc. | Human serum albumin linkers and conjugates thereof |
| HRP20170374T1 (hr) * | 2008-09-26 | 2017-05-05 | Ucb Biopharma Sprl | Biološki proizvodi |
| KR101740066B1 (ko) * | 2008-12-05 | 2017-05-25 | 글락소 그룹 리미티드 | 프로테아제 저항성 폴리펩티드를 선택하는 방법 |
| JP6086528B2 (ja) * | 2009-08-06 | 2017-03-01 | ノヴォ・ノルディスク・ヘルス・ケア・アーゲー | 長期のインビボ有効性を有する成長ホルモン |
| GB201005063D0 (en) * | 2010-03-25 | 2010-05-12 | Ucb Pharma Sa | Biological products |
| MX2012003939A (es) * | 2009-09-30 | 2012-07-30 | Glaxo Group Ltd | Fusiones y conjugados de farmaco. |
| WO2012158818A2 (en) * | 2011-05-16 | 2012-11-22 | Fabion Pharmaceuticals, Inc. | Multi-specific fab fusion proteins and methods of use |
| AU2012335496B2 (en) * | 2011-11-11 | 2017-05-11 | Ucb Biopharma Sprl | Albumin binding antibodies and binding fragments thereof |
-
2014
- 2014-08-29 MX MX2016002539A patent/MX371328B/es active IP Right Grant
- 2014-08-29 CN CN201480056265.1A patent/CN105899532B/zh active Active
- 2014-08-29 DK DK14839630.2T patent/DK3039038T3/da active
- 2014-08-29 JP JP2016538860A patent/JP6422977B2/ja active Active
- 2014-08-29 CA CA2922618A patent/CA2922618C/en active Active
- 2014-08-29 WO PCT/KR2014/008106 patent/WO2015030539A1/en not_active Ceased
- 2014-08-29 RU RU2016105586A patent/RU2661087C2/ru active
- 2014-08-29 AU AU2014312456A patent/AU2014312456B2/en active Active
- 2014-08-29 UA UAA201601685A patent/UA117493C2/uk unknown
- 2014-08-29 EP EP19192902.5A patent/EP3632930A1/en not_active Withdrawn
- 2014-08-29 EP EP14839630.2A patent/EP3039038B1/en active Active
- 2014-08-29 ES ES14839630T patent/ES2866848T3/es active Active
- 2014-08-29 BR BR112016004355A patent/BR112016004355A2/pt not_active Application Discontinuation
- 2014-08-29 PL PL14839630T patent/PL3039038T3/pl unknown
- 2014-09-01 KR KR1020140115673A patent/KR101576561B1/ko active Active
-
2015
- 2015-09-25 KR KR1020150136164A patent/KR20150118565A/ko not_active Ceased
-
2016
- 2016-02-29 US US15/056,299 patent/US9879077B2/en active Active
- 2016-02-29 PH PH12016500403A patent/PH12016500403A1/en unknown
-
2017
- 2017-09-27 US US15/717,528 patent/US10618953B2/en active Active
-
2018
- 2018-06-01 JP JP2018106308A patent/JP6800180B2/ja active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK3039038T3 (da) | Fusionskonstruktion med antiserumalbumin-fab-effektordel, og fremstillingsmetode dertil | |
| IL246287B (en) | Fabs-in-tandem immunoglobulin and uses thereof | |
| CL2016001460A1 (es) | Anticuerpo pdi-1, fragmento unificador antígeno de la misma y aplicación médica de la misma | |
| HUE061173T2 (hu) | Applikációs módszer és applikációs eszköz | |
| EP2966680A4 (en) | LAMINATE AND METHOD FOR THE MANUFACTURE THEREOF | |
| DK3030092T3 (da) | System og fremgangsmåde til fremstilling af et ekstruderet proteinprodukt | |
| EP2943512A4 (en) | BOVINE FUSION ANTIBODY | |
| FI20135896L (fi) | Komposiittikappale ja menetelmä sen valmistamiseksi | |
| PT3712174T (pt) | Anticorpos e fragmentos anti-vista | |
| LT2970123T (lt) | Omekamtivo mekarbilo druska ir jos gamybos būdas | |
| DK3683235T3 (da) | Anti-IL-33-antistoffer og anvendelser deraf | |
| EP2945678A4 (en) | PATIENT INTERFACE AND METHOD FOR THE PRODUCTION THEREOF | |
| EP2944463A4 (en) | MOLDING FILM AND MANUFACTURING METHOD THEREFOR | |
| FI20135175L (fi) | Aktuaattori ja menetelmä aktuaattorin parantamiseksi | |
| HUE043273T2 (hu) | Fúziós fehérje | |
| PL3052672T3 (pl) | Punktowe połączenie zgrzewane o wysokiej wytrzymałości i wysokim kształtowaniu oraz sposób jego wytwarzania | |
| DK3079719T3 (da) | ANTI-SIGLEC-8-antistoffer og fremgangsmåder til anvendelse deraf | |
| EP2958188A4 (en) | MODEN CONVERTER AND MANUFACTURING METHOD THEREFOR | |
| CL2016000219A1 (es) | Proteinas de fusión terapéutica. | |
| PL2943820T3 (pl) | Matryca soczewek i sposób wytwarzania matrycy soczewek | |
| DK2962113T3 (da) | Systemer og fremgangsmåder med anti-p40-antistoffer | |
| LT3038656T (lt) | Glikozaminoglikano junginys, jo gamybos būdas ir panaudojimas | |
| DK3620743T3 (da) | Entalpivekslerelement og fremgangsmåde til fremstilling | |
| HUE042170T2 (hu) | Eljárás csomópont ultrahangos hegesztést követõen fennálló tömörítési fokának meghatározására | |
| EP2979857A4 (en) | LAYER BODY, BARRIER LAYER AND MANUFACTURING METHOD THEREFOR |